X. Cabarrocas

发表

Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine

J. Pascual, P. Ferrer, R. Falk, 2001, European Neurology.

Almotriptan Improves Response Rates When Treatment Is Within 1 Hour of Migraine Onset

A. Dowson, H. Massiou, J. Láinez, 2004, Headache.

Almotriptan is an Effective and Well-Tolerated Treatment for Migraine Pain: Results of A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

H. Massiou, J. Láinez, X. Cabarrocas, 2002, Cephalalgia : an international journal of headache.

Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.

X. Cabarrocas, 2001, Clinical therapeutics.

Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial.

J. Costa, A. Martinez-Tobed, J. Jansat, 2006, International journal of clinical pharmacology and therapeutics.

Within‐Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the Better

J. Pascual, X. Cabarrocas, 2002, Headache.

Almotriptan, a new anti-migraine agent: a review.

J. Palacios, J. Gras, J. Llenas, 2006, CNS drug reviews.

Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine

G. Allais, C. Benedetto, G. Bussone, 2006, Neurological Sciences.

Meta-Analysis of Oral Triptans: Reply

X. Cabarrocas, 2004 .

Long‐term Efficacy and Safety of Oral Almotriptan: Interim Analysis of a 1‐Year Open Study

P. Ferrer, X. Cabarrocas, Xavier Cabarrocas, 2001, Headache.